Electrocardiographic characteristics of bladder cancer patients receiving preoperative chemotherapy combined with immunotherapy.

"CONFLICT OF INTEREST STATEMENT The authors declare no conflict of interest."

"FUNDING INFORMATION This work was supported by grants from the National Natural Science Foundation of China (82170327 and 82370332 to T.L.), the National Natural Science Foundation of China (82100341 to Z.Z.), the Tianjin Natural Science Foundation (21JCQNJC01680 to Z.Z.), and the Tianjin Key Medical Discipline (Specialty) Construction Project (TJYXZDXK‐029A)."

"This was a retrospective analysis of two clinical trials (ClinicalTrials.gov identifiers: NCT04730219 and NCT04730232) between September 2020 and June 2022. Briefly, these two ongoing phase II studies were designed to determine the safety and efficacy of tislelizumab in combination with nab‐paclitaxel for MIBC and NMIBC patients prior to cystectomy or transurethral resection biopsy at the Urology Department of the Second Hospital of Tianjin Medical University. The study received approval from the hospital's ethics committee. The inclusion criteria were as follows: (1) histopathologically diagnosed with BC and (2) treated with preoperative chemotherapy combined with immunotherapy (tislelizumab plus nab‐paclitaxel (TnP)) every 21 days. In total, patients with MIBC and NMIBC received 3 and 4 cycles of TnP therapy, respectively; (3) underwent baseline and serial cardiovascular assessments (including ECG, cardiac biomarkers, and echocardiography). In particular, all patients were assessed on the first day of each cycle of TnP and before subsequent surgical treatment. Exclusion criteria: (1) incomplete clinical data; (2) poor‐quality ECG; and (3) patients with uncontrolled or severe cardiovascular disease."